| |
|
|
|
|
|
|
|||
|
Blood, Vol. 96 No. 1 (July 1), 2000:
pp. 145-148
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From N.V. Organon, Research and Development, Oss, The Netherlands;
and Department of Medicine, Institute of Medical Science, University of
Toronto, Toronto, Canada.
The coagulation protease factor Xa induces cellular
responses implicated in cardiovascular and inflammatory disease.
Effector-cell protease receptor 1 (EPR-1) is a functionally
characterized receptor of factor Xa, and the EPR-1
complementary DNA (cDNA) was published. Remarkably, the cDNA encoding
an inhibitor of apoptosis, survivin, is reportedly identical to that of
EPR-1 except for a few nucleotide differences and its
orientation opposite to EPR-1. To isolate the EPR-1
cDNA and gene, we surveyed gene databases for expressed sequence tags
(ESTs) that could be derived from EPR-1. All ESTs with strong
homology to EPR-1/survivin were derived from survivin and could not encode EPR-1. By polymerase chain reaction and Southern blot hybridization, EPR-1 was not detectable in the human or
murine genome, but survivin was. Our data suggest that EPR-1 is
either highly cell-specific or the published EPR-1 cDNA
includes sequences from clones derived from survivin messenger
RNA. The means by which factor Xa mediates its cellular effects
requires further evaluation.
(Blood. 2000;96:145-148)
In addition to their role in maintaining hemostasis,
coagulation proteases elicit various cellular responses in vascular, mesenchymal, and inflammatory cell types that have been implicated in
cardiovascular disease,1 inflammation,2,3 and
tumor metastasis.4 The serine protease factor Xa is one of
the major late-stage enzymes in the blood coagulation cascade. Factor
Xa acts in concert with the nonenzymatic cofactor, factor Va, to convert prothrombin into thrombin, which induces the formation of the
fibrin clot by proteolysis of fibrinogen. In addition, factor Xa has
been shown to induce mitogenesis,5
vasorelaxation,6 and proinflammatory
responses.7,8
A cellular receptor for factor Xa, designated effector-cell protease
receptor 1 (EPR-1), was described by D. C. Altieri and colleagues. The
human receptor was originally identified and characterized with a
monoclonal antibody raised against factor V/Va,9 which also
reacted with a second generation of antibodies raised against leukemic
T cells.10 The human EPR-1 complementary DNA (cDNA) sequence, published in 1994,10 was obtained by
immunoscreening an expression library of a T-cell line (MLT) with one
of the second-generation antibodies (2E1). This yielded a partial cDNA
clone that was used to screen additional cDNA libraries derived from
T-cell lines and human umbilical vein endothelial cell lines. From 28 independent clones, a consensus EPR-1 cDNA sequence of 1165 base pairs (bp) was derived, which was predicted to encode a protein of
337 amino acids with no structural homology to any other known protein
class.10 In a subsequent paper, it was reported that there
actually exist 2 splice variants of the EPR-1 messenger RNA
(mRNA).11 In addition to the cDNA sequence described in the
first paper,10 a second variant was described that had
retained a 451-bp intervening sequence. The presence of the intervening
sequence resulted in preliminary termination of translation of EPR-1,
resulting in a truncated protein, designated EPR-1b, that localized in
the nucleus.11 More recently, Altieri and coworkers
reported the cloning and characterization of the human survivin
gene, which encodes an inhibitor of apoptosis.12 Most
strikingly, the coding strand for survivin was almost identical
to the long variant of the EPR-1 mRNA read in the opposite
orientation.12
In this report we describe our attempts to isolate the human and murine
EPR-1 cDNAs and genes. Our data suggest that EPR-1 is either a
unique property of specific cell lines or that the published
EPR-1 cDNA contains sequence errors or includes sequences from
clones that were actually derived from survivin mRNA.
Northern hybridization
Polymerase chain reaction analysis
Southern hybridization Probes C and D were separated electrophoretically on 2% agarose gels. Oligonucleotide probe E was end-labeled with [32P]ATP. Genomic DNA from mouse
embryonic stem cells (15 µg per lane) or P1 artificial chromosome
(PAC) genomic DNA (4 µg per lane) was separated
on a 0.7% agarose gel following restriction enzyme digestion. After
transfer to a nylon filter, the membranes were hybridized in Quik-Hyb
(Stratagene, La Jolla, CA) for 1 hour and finally washed
with 0.1% SDS, 0.5 × SSC at 55°C. The filters were
then exposed for autoradiography.
The mRNAs for EPR-1 and survivin can be
distinguished by hybidization with single-stranded probes. We have used
probes complementary to sequences at the 5' or 3'
ends of either survivin or EPR-1 to evaluate
transcription of the 2 genes from a variety of human tissues by
Northern blot analysis. As seen in Figure
1A, survivin was detected as
a 1.9-kilobase (kb) band in RNA from thymus, in agreement with data
from Altieri and coworkers.12 Additionally, the 1.9-kb band
was found in RNA from human testis, small intestine, and colon (Figure
1A). However, hybridization of the Northern blots with 2 EPR-1-specific probes yielded 2 different patterns, indicating
that the 2 probes recognized different RNA species. With probe A,
directed to the first 226 nucleotides of EPR-1 plus the first
94 nucleotides of the "intervening sequence," a hybridization pattern similar to that shown by Altieri and coworkers13
was obtained. This probe hybridized with a band of 2.0 kb in small intestine and colon and to fainter bands at 0.9 and 6.0 kb in all RNAs
on the blot. Probe B, directed to nucleotides 664 to 972 of EPR-1
(numbering corresponds to GenBank L26245), hybridized to a band of
1.6 kb in all tissues and 1.0 kb in spleen and small intestine (Figure
1A). The identity of the transcripts detected with the
EPR-1 probes is unclear; however, if they are derived from a
single transcript, they reflect a complex pattern of
tissue-specific alternative splicing events.
Taken together, our data suggest that EPR-1 is either a unique
property of specific cell lines or that the EPR-1 cDNA contains sequence errors or includes sequences from clones that were actually derived from survivin mRNA. It follows, therefore, that the
means by which factor Xa mediates its cellular effects should be
further evaluated. There is currently solid evidence supporting the
concept that one or more alternative cellular receptors for factor Xa exist and, indeed, cell biological studies show that EPR-1 does not
mediate the cellular effects of factor Xa in various cell types.8,18,19 For example, factor Xa has been shown to
increase intracellular free calcium levels and phosphoinositide
turnover.16,18 The native (zymogen) form of factor X was
inactive,18 and a role for PAR2, a member of the
protease-activator receptor (PAR) class of G protein-coupled receptors
has been suggested.19,20 Another candidate receptor for
factor Xa is the recently discovered PAR4,21,22 which was
reported to be activated at high (nonphysiologic) concentrations of
factor Xa.22 Finally, several cDNAs encoding receptors
homologous to the PARs have been identified in EST sequencing projects.23,24 It is anticipated that one or more of these may prove to be a functional receptor for factor Xa, findings that will
provide further insights into the biologically wide spectrum of
activities of factor Xa and other similar serine proteases.
We thank Mr P. Vink, Ms S. Pollefeyt, and Ms M. Steiner-Mosonyi for
technical assistance, Dr P. v. d. Spek for bioinformatics, and
Incyte Pharmaceuticals for use of the LifeSeqGold database.
Submitted November 17, 1999; accepted February 14, 2000.
Reprints: Guido J. R. Zaman, N.V. Organon, PO Box 20, 5340 BH
Oss, The Netherlands; e-mail: g.zaman{at}organon.oss.akzonobel.nl.
The publication costs of this
article were defrayed in part by
page charge payment. Therefore,
and solely to indicate this fact,
this article is hereby marked
"advertisement"
in accordance with 18 U.S.C.
section 1734.
1.
Ross R.
The pathogenesis of atherosclerosis: a perspective for the 1990s.
Nature.
1993;362:801-809[Medline]
[Order article via Infotrieve].
2.
Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A.
Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin.
Am J Pathol.
1994;144:975-985[Abstract].
3.
Sower LE, Froelich CJ, Carney DH, Fenton JW III, Klimpel GR.
Thrombin induces IL-6 production in fibroblasts and epithelial cells.
J Immunol.
1995;155:895-901[Abstract].
4.
Mueller BM, Reisfeld RA, Edgington TS, Ruf W.
Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis.
Proc Natl Acad Sci U S A.
1992;89:11832-11836
5.
Gasic GP, Arenas CP, Gasic TB, Gasic GJ.
Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells.
Proc Natl Acad Sci U S A.
1992;89:2317-2320
6.
Schaeffer P, Mares A-M, Dol F, Bono F, Herbert J-M.
Coagulation Factor Xa induces endothelium-dependent relaxations in rat aorta.
Circ Res.
1997;81:824-828
7.
Cirino G, Cicala C, Bucci M, et al.
Factor Xa as an interface between coagulation and inflammation: molecular mimicry of Factor Xa association with Effector Cell Protease Receptor-1 induces acute inflammation in vivo.
J Clin Invest.
1997;99:2446-2451[Medline]
[Order article via Infotrieve].
8.
Senden NHM, Jeunhomme TMAA, Heemskerk JWM, et al.
Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells.
J Immunol.
1998;161:4318-4324
9.
Altieri DC, Edgington TS.
Identification of effector cell protease receptor-1: a leukocyte-distributed receptor for the serine protease Factor Xa.
J Immunol.
1990;145:246-253[Abstract].
10.
Altieri DC.
Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease Factor Xa.
J Biol Chem.
1994;269:3139-3142
11.
Altieri DC.
Splicing of effector cell protease receptor-1 mRNA is modulated by an unusual retained intron.
Biochemistry.
1994;33:13848-13855[Medline]
[Order article via Infotrieve].
12.
Ambrosini G, Adida C, Altieri DC.
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.
Nat Med.
1997;3:917-921[Medline]
[Order article via Infotrieve].
13.
Ambrosini G, Adida C, Sirugo G, Altieri DC.
Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting.
J Biol Chem.
1998;273:11177-11182
14.
Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC.
Developmentally regulated expression of the novel cancer anti-apoptosis gene Survivin in human and mouse differentiation.
Am J Pathol.
1998;152:43-49[Abstract].
15.
Bono F, Hérault J-P, Avril C, Schaeffer P, Lormeau J-C, Herbert J-M.
Human umbilical vein endothelial cells express high affinity receptors for Factor Xa.
J Cell Physiol.
1997;172:36-43[Medline]
[Order article via Infotrieve].
16.
Herbert J-M, Bono F, Hérault J-P, et al.
Effector Protease Receptor 1 mediates the mitogenic activity of Factor Xa for vascular smooth muscle cells in vitro and in vivo.
J Clin Invest.
1998;101:993-1000[Medline]
[Order article via Infotrieve].
17.
Conway EM, Pollefeyt S, Cornelissen J, et al.
Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions.
Blood.
2000;95:1435-1442
18.
Camerer E, Røttingen J-A, Iversen J-G, Prydz H.
Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active.
J Biol Chem.
1996;271:29034-29042
19.
Camerer E, Røttingen J-A, Gjernes, et al.
Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene.
J Biol Chem.
1999;274:32225-32233
20.
Vu T-K, Hung D, Wheaton V, Coughlin S.
Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.
Cell.
1991;64:1057-1068[Medline]
[Order article via Infotrieve].
21.
Kahn ML, Zheng Y-W, Huang W, et al.
A dual thrombin receptor system for platelet activation.
Nature.
1998;394:690-694[Medline]
[Order article via Infotrieve].
22.
Xu W-F, Andersen H, Whitmore TE, et al.
Cloning and characterization of human protease-activated receptor 4.
Proc Natl Acad Sci U S A.
1998;95:6642-6646
23.
Li Y, Gocayne JD, Ruben SM.
G-protein receptor HIBEB69. WO 96/39438-A1; 1996.
24.
Coleman R, Au-Young J, Bandman O, Seilhamer JJ.
Thrombin receptor homolog. WO 96/40040-A2; 1996.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||